Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 + Serplulimab in advanced solid tumors
NCT06848699Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in solid tumor cancer, non-small cell lung cancer (NSCLC), sponsored by Henlius. Started Feb 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
solid tumor cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06848699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848699.